164 related articles for article (PubMed ID: 32936345)
1. No Difference of Adalimumab Pharmacokinetics When Dosed at 40 mg Every Week or 80 mg Every Other Week in IBD Patients in Clinical Remission After Adalimumab Dose Intensification.
Paul S; Williet N; Nancey S; Veyrard P; Boschetti G; Phelip JM; Flourie B; Roblin X
Dig Dis Sci; 2021 Aug; 66(8):2744-2749. PubMed ID: 32936345
[TBL] [Abstract][Full Text] [Related]
2. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.
Roblin X; Rinaudo M; Del Tedesco E; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
Am J Gastroenterol; 2014 Aug; 109(8):1250-6. PubMed ID: 24913041
[TBL] [Abstract][Full Text] [Related]
3. Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study.
Taxonera C; Martínez-Montiel MP; Barreiro-de-Acosta M; Vera I; Lorente R; Vega P; Diz-Lois MT; Fuentes Coronel AM; Pérez Calle JL; Casis B; Ferreiro-Iglesias R; Calvo M; Olivares D; Alba C
Therap Adv Gastroenterol; 2021; 14():17562848211056157. PubMed ID: 35116079
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease.
Bodini G; Giannini EG; Savarino V; Del Nero L; Pellegatta G; De Maria C; Baldissarro I; Savarino E
Scand J Gastroenterol; 2016 Sep; 51(9):1081-6. PubMed ID: 27207330
[TBL] [Abstract][Full Text] [Related]
5. Treatment With Adalimumab 80 mg Every Other Week in Inflammatory Bowel Disease: Results of Treatment Intensification in Clinical Practice.
Calvo Moya M; González Lama Y; Ruíz Antorán B; Omella Usieto I; El Hajra Martinez I; Santos Pérez E; Menchén Viso B; Matallana Royo V; González Partida I; de Lucas Tellez de Meneses R; Bella Castillo P; González Rodriguez M; Vera Mendoza MI
Crohns Colitis 360; 2023 Jan; 5(1):otac051. PubMed ID: 36785555
[TBL] [Abstract][Full Text] [Related]
6. Validation of a population pharmacokinetic model of adalimumab in a cohort of patients with inflammatory bowel disease.
Martínez-Romero GJ; Alvariño A; Hinojosa E; Mora M; Oltra L; Maroto N; Ferrer I; Hinojosa MD; Hinojosa JE
Rev Esp Enferm Dig; 2019 Jun; 111(6):431-436. PubMed ID: 31021170
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and clinical monitoring through posologic changes in adalimumab intensification regimen from 40 mg every week to 80 mg every other week.
Diz-Lois Palomares MªT; Porta Sánchez Á; Elberdin Pazos L; González Conde B; Outeda Macías M; Vázquez Rey MT; Estévez Prieto E; Martín Herranz I; Alonso Aguirre P
Rev Esp Enferm Dig; 2022 Dec; 114(12):708-712. PubMed ID: 35170328
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease.
Kato M; Sugimoto K; Ikeya K; Takano R; Matsuura A; Miyazu T; Ishida N; Tamura S; Tani S; Yamade M; Hamaya Y; Iwaizumi M; Osawa S; Furuta T; Hanai H
PLoS One; 2021; 16(7):e0254548. PubMed ID: 34242369
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab Concentration Changes After Dose Escalation in Inflammatory Bowel Disease.
Jasurda JS; McCabe RP; Vaughn BP
Ther Drug Monit; 2021 Oct; 43(5):645-651. PubMed ID: 33346627
[TBL] [Abstract][Full Text] [Related]
10. Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial.
Nakase H; Motoya S; Matsumoto T; Watanabe K; Hisamatsu T; Yoshimura N; Ishida T; Kato S; Nakagawa T; Esaki M; Nagahori M; Matsui T; Naito Y; Kanai T; Suzuki Y; Nojima M; Watanabe M; Hibi T;
Aliment Pharmacol Ther; 2017 Nov; 46(9):873-882. PubMed ID: 28884856
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulator comedication promotes the reversal of anti-drug antibody-mediated loss of response to anti-TNF therapy in inflammatory bowel disease.
Stallhofer J; Guse J; Kesselmeier M; Grunert PC; Lange K; Stalmann R; Eckardt V; Stallmach A
Int J Colorectal Dis; 2023 Feb; 38(1):54. PubMed ID: 36840779
[TBL] [Abstract][Full Text] [Related]
12. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M
Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab for Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta-Analysis.
Chen X; Hou J; Yuan Y; Huang C; Liu T; Mo C; Li H; Chen B; Xu Q; Hou Z; He W; Liu F
BioDrugs; 2016 Jun; 30(3):207-17. PubMed ID: 27120055
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts.
Derikx LAAP; Dolby HW; Plevris N; Lucaciu L; Rees CS; Lyons M; Siakavellas SI; Constantine-Cooke N; Jenkinson P; Su S; O'Hare C; Kirckpatrick L; Merchant LM; Noble C; Arnott ID; Jones GR; Lees CW
J Crohns Colitis; 2021 Dec; 15(12):2011-2021. PubMed ID: 34089587
[TBL] [Abstract][Full Text] [Related]
15. Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment.
Brandse JF; Vos LM; Jansen J; Schakel T; Ponsioen CI; van den Brink GR; D'Haens GR; Löwenberg M
J Crohns Colitis; 2015 Nov; 9(11):973-81. PubMed ID: 26116557
[TBL] [Abstract][Full Text] [Related]
16. Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases.
Gonczi L; Kurti Z; Rutka M; Vegh Z; Farkas K; Lovasz BD; Golovics PA; Gecse KB; Szalay B; Molnar T; Lakatos PL
BMC Gastroenterol; 2017 Aug; 17(1):97. PubMed ID: 28789636
[TBL] [Abstract][Full Text] [Related]
17. Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up.
Chen DY; Chen YM; Hsieh TY; Hung WT; Hsieh CW; Chen HH; Tang KT; Lan JL
Rheumatology (Oxford); 2016 Jan; 55(1):143-8. PubMed ID: 26324949
[TBL] [Abstract][Full Text] [Related]
18. Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring.
Assa A; Matar M; Turner D; Broide E; Weiss B; Ledder O; Guz-Mark A; Rinawi F; Cohen S; Topf-Olivestone C; Shaoul R; Yerushalmi B; Shamir R
Gastroenterology; 2019 Oct; 157(4):985-996.e2. PubMed ID: 31194979
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics and Immunogenicity of Adalimumab in Adult Patients with Moderate-to-Severe Hidradenitis Suppurativa.
Nader A; Beck D; Noertersheuser P; Williams D; Mostafa N
Clin Pharmacokinet; 2017 Sep; 56(9):1091-1102. PubMed ID: 28066879
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic model for analysis of adalimumab administered for Crohn's disease.
Kimura K; Yoshida A; Takayanagi R; Yamada Y
Biopharm Drug Dispos; 2018 Jun; 39(6):283-288. PubMed ID: 29790586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
